Dendritic cells (DCs) are particularly well-suited for BC immunotherapy due to their ability to sensitize CD8+ T cells and also CD4+ T cells capable of generating memory T cells and contribute with additional cytotoxicity against tumors (66). Here, CD8A is linked to breast cancer.